Since methyldopa decreased the VEGF level in severe preeclampsia patients by 10% at the dose of 250 mg and by 57% at the dose of 500 mg [63], it can be assumed that administering methyldopa together with flavonoids, especially quercetin, will allow lower doses of the drug to be used, which may be beneficial in reducing the risk of side effects from methyldopa. The gene discussed is VEGFA; the disease is preeclampsia.